Every GLP-1 Brand Available in 2026: FDA-Approved vs Compounded, Active Ingredients, and Which One Matches Your Clinical Profile

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Seven FDA-approved GLP-1 medications are available as of April 2026: Ozempic, Wegovy, Rybelsus, Mounjaro, Zepbound, Saxenda, and Victoza, containing either semaglutide, tirzepatide, or liraglutide
• Compounded semaglutide and tirzepatide became widely available during the 2022-2024 FDA shortage period and remain legal under 503A pharmacy rules when brand-name versions are on the shortage list
• The active ingredient matters more than the brand name for predicting side effects, efficacy, and dosing schedule, but delivery mechanism (injection vs oral) changes absorption and dosing requirements
• Tirzepatide (dual GLP-1/GIP agonist) shows 15-22% average weight loss in trials vs 10-15% for semaglutide (GLP-1 only), but head-to-head real-world data remains limited

Direct answer (40-60 words)

GLP-1 brands fall into three categories: semaglutide-based (Ozempic, Wegovy, Rybelsus, compounded semaglutide), tirzepatide-based (Mounjaro, Zepbound, compounded tirzepatide), and older liraglutide formulations (Saxenda, Victoza). The active ingredient determines efficacy and side effects. Brand vs compounded versions differ in FDA approval status, cost, and availability but contain identical active molecules.

Table of contents

1. The brand landscape: FDA-approved vs compounded in 2026
2. Semaglutide brands: Ozempic, Wegovy, Rybelsus, and compounded versions
3. Tirzepatide brands: Mounjaro, Zepbound, and compounded versions
4. Liraglutide brands: Saxenda and Victoza
5. What most articles get wrong about "brand vs generic"
6. Active ingredient comparison: semaglutide vs tirzepatide vs liraglutide
7. The delivery mechanism question: injection vs oral
8. FDA shortage status and compounding legality in 2026
9. The FormBlends Brand Selection Framework
10. Cost comparison: brand-name vs compounded
11. When brand-name is worth the premium and when it's not
12. The contrary view: why some clinicians avoid compounded versions
13. FAQ
14. Sources

The brand landscape: FDA-approved vs compounded in 2026

As of April 2026, the GLP-1 medication landscape includes seven FDA-approved brands and two widely available compounded options:

Brand Name	Active Ingredient	FDA Approval	Indication	Delivery Method	Manufacturer
Ozempic	Semaglutide	2017	Type 2 diabetes	Weekly injection	Novo Nordisk
Wegovy	Semaglutide	2021	Weight management	Weekly injection	Novo Nordisk
Rybelsus	Semaglutide	2019	Type 2 diabetes	Daily oral tablet	Novo Nordisk
Mounjaro	Tirzepatide	2022	Type 2 diabetes	Weekly injection	Eli Lilly
Zepbound	Tirzepatide	2023	Weight management	Weekly injection	Eli Lilly
Saxenda	Liraglutide	2014	Weight management	Daily injection	Novo Nordisk
Victoza	Liraglutide	2010	Type 2 diabetes	Daily injection	Novo Nordisk
Compounded semaglutide	Semaglutide	Not FDA-approved	Off-label weight management or diabetes	Weekly injection (typically)	Various 503A pharmacies
Compounded tirzepatide	Tirzepatide	Not FDA-approved	Off-label weight management or diabetes	Weekly injection (typically)	Various 503A pharmacies

The distinction between "diabetes" and "weight management" indications is regulatory, not pharmacological. Ozempic and Mounjaro are approved for diabetes but prescribed off-label for weight loss. Wegovy and Zepbound contain identical molecules at identical or similar doses but carry weight-management indications and different insurance coverage rules.

Semaglutide brands: Ozempic, Wegovy, Rybelsus, and compounded versions

Semaglutide is a GLP-1 receptor agonist, meaning it activates only the GLP-1 receptor (not GIP). All semaglutide brands contain the same 31-amino-acid peptide with identical receptor binding.

Ozempic was the first weekly semaglutide injection, approved in 2017 for type 2 diabetes. Dosing starts at 0.25 mg weekly and escalates to maintenance doses of 0.5 mg, 1 mg, or 2 mg weekly. The 2 mg dose was added in 2022 after the SUSTAIN FORTE trial showed additional A1C reduction (Frías et al., Diabetes Care, 2021).

Wegovy is the same semaglutide molecule at a higher maximum dose (2.4 mg weekly). It was approved in 2021 specifically for chronic weight management in adults with BMI over 30 or BMI over 27 with weight-related comorbidities. The STEP trial program (Wilding et al., New England Journal of Medicine, 2021) showed 14.9% average weight loss at 68 weeks vs 2.4% for placebo.

Rybelsus is oral semaglutide, approved in 2019. The tablet contains semaglutide plus an absorption enhancer (SNAC) that allows the peptide to survive stomach acid and cross the intestinal lining. Dosing is 3 mg, 7 mg, or 14 mg daily, taken on an empty stomach with no food or drink for 30 minutes after. Bioavailability is roughly 1% (vs near 100% for injections), so the daily oral dose is much higher than the weekly injection dose to achieve similar blood levels. The PIONEER 1 trial (Aroda et al., Diabetes Care, 2019) showed A1C reduction of 1.4% at 14 mg daily.

Compounded semaglutide became widely available in 2022 when Novo Nordisk reported shortages of Ozempic and Wegovy to the FDA. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, state-licensed compounding pharmacies can prepare patient-specific prescriptions of drugs on the FDA shortage list. Compounded semaglutide is typically supplied as lyophilized powder requiring reconstitution with bacteriostatic water, then injected weekly. Dosing mirrors Wegovy (0.25 mg to 2.4 mg escalation). Compounded versions have not undergone FDA review for safety or efficacy and are not interchangeable with brand-name products.

The semaglutide molecule is identical across all four products. The differences are delivery mechanism (injection vs oral), maximum dose (2 mg for Ozempic, 2.4 mg for Wegovy and compounded), and regulatory status.

Tirzepatide brands: Mounjaro, Zepbound, and compounded versions

Tirzepatide is a dual GLP-1 and GIP receptor agonist. GIP (glucose-dependent insulinotropic polypeptide) is a second incretin hormone that enhances insulin secretion and may have independent effects on fat metabolism. The dual mechanism appears to produce greater weight loss than GLP-1 agonism alone, though the exact contribution of GIP is still debated (Samms et al., Cell Metabolism, 2021).

Mounjaro was approved in May 2022 for type 2 diabetes. Dosing starts at 2.5 mg weekly and escalates to 5 mg, 7.5 mg, 10 mg, 12.5 mg, or 15 mg weekly. The SURPASS clinical trial program showed A1C reductions of 1.9% to 2.4% depending on dose, superior to semaglutide 1 mg in head-to-head comparison (Frías et al., New England Journal of Medicine, 2021).

Zepbound is the same tirzepatide molecule approved in November 2023 for chronic weight management. Maximum dose is 15 mg weekly. The SURMOUNT-1 trial (Jastreboff et al., New England Journal of Medicine, 2022) showed 22.5% average weight loss at 15 mg vs 2.4% for placebo at 72 weeks, the highest weight loss ever recorded in a phase 3 obesity trial for a non-surgical intervention.

Compounded tirzepatide followed the same legal pathway as compounded semaglutide. Tirzepatide appeared on the FDA shortage list in 2023, allowing 503A pharmacies to compound patient-specific prescriptions. Compounded tirzepatide is typically supplied as lyophilized powder for reconstitution and weekly injection, dosed identically to Zepbound (2.5 mg to 15 mg escalation).

The tirzepatide molecule is identical across Mounjaro, Zepbound, and compounded versions. The distinction is indication (diabetes vs weight management) and regulatory approval status.

Liraglutide brands: Saxenda and Victoza

Liraglutide is a first-generation GLP-1 agonist with a shorter half-life than semaglutide or tirzepatide, requiring daily rather than weekly injection.

Victoza was approved in 2010 for type 2 diabetes at doses of 0.6 mg, 1.2 mg, or 1.8 mg daily. The LEADER trial (Marso et al., New England Journal of Medicine, 2016) showed cardiovascular benefit in diabetic patients, establishing GLP-1 agonists as a cardioprotective drug class.

Saxenda is the same liraglutide molecule approved in 2014 for weight management at a higher dose: 3 mg daily. The dose escalates from 0.6 mg over five weeks to reduce nausea. Average weight loss in the SCALE trial was 8% at 56 weeks (Pi-Sunyer et al., New England Journal of Medicine, 2015), lower than semaglutide or tirzepatide but still clinically meaningful.

Liraglutide is rarely compounded because the daily injection requirement and lower efficacy make semaglutide and tirzepatide more attractive for both patients and providers. Saxenda and Victoza remain on the market but represent older technology in a rapidly advancing field.

What most articles get wrong about "brand vs generic"

The most common error in GLP-1 content is calling compounded semaglutide or tirzepatide "generic" versions of Ozempic, Wegovy, Mounjaro, or Zepbound. This is legally and pharmacologically incorrect.

A generic drug is an FDA-approved medication that contains the same active ingredient, strength, dosage form, and route of administration as a brand-name drug. Generics undergo abbreviated new drug application (ANDA) review by the FDA and must demonstrate bioequivalence to the reference product. Once approved, generics are interchangeable with brand-name drugs at the pharmacy level.

A compounded medication is prepared by a state-licensed pharmacy in response to an individual prescription. Compounded drugs are not FDA-approved, have not undergone bioequivalence testing, and are not interchangeable with brand-name products. Compounding is legal under Section 503A when a prescriber determines that an FDA-approved product does not meet a patient's needs, or when the FDA-approved version is on the agency's drug shortage list.

As of April 2026, no generic versions of semaglutide or tirzepatide exist. Wegovy's patent protection extends to 2032. Ozempic's to 2031. Mounjaro and Zepbound have exclusivity through the early 2030s. The first true generics are a decade away.

Compounded semaglutide and tirzepatide are not generics. They are non-FDA-approved alternatives available during shortage periods or when a provider writes a patient-specific prescription justifying compounding. The distinction matters for insurance coverage, liability, and patient expectations about regulatory oversight.

Active ingredient comparison: semaglutide vs tirzepatide vs liraglutide

The three active ingredients differ in receptor activity, half-life, and clinical outcomes:

Feature	Liraglutide	Semaglutide	Tirzepatide
Receptor target	GLP-1 only	GLP-1 only	GLP-1 + GIP (dual)
Half-life	13 hours	7 days	5 days
Injection frequency	Daily	Weekly	Weekly
Average weight loss (phase 3 trials)	8% at 56 weeks	15% at 68 weeks	22.5% at 72 weeks
A1C reduction in diabetes	1.0-1.5%	1.5-2.0%	1.9-2.4%
Nausea rate (maintenance dose)	20-25%	15-20%	12-18%
Cardiovascular outcomes data	Yes (LEADER)	Yes (SELECT)	Ongoing (SURPASS-CVOT)

Liraglutide is the oldest and least potent. Daily injection is a compliance barrier. It remains a reasonable option for patients who cannot tolerate semaglutide or tirzepatide, or who prefer daily dosing for psychological reasons (some patients report feeling more "in control" with daily medication).

Semaglutide is the most-prescribed GLP-1 agonist as of 2026. Seven-day half-life allows weekly dosing. The SELECT trial (Lincoff et al., New England Journal of Medicine, 2023) showed 20% reduction in major adverse cardiovascular events in patients with established cardiovascular disease, expanding the indication beyond diabetes and weight loss to secondary prevention.

Tirzepatide produces the greatest weight loss and A1C reduction but has the shortest post-approval track record (approved 2022-2023 vs 2017-2021 for semaglutide). The dual GIP/GLP-1 mechanism is novel. Some patients report fewer gastrointestinal side effects on tirzepatide than semaglutide, though trial data shows similar nausea rates. The SURMOUNT-2 trial in diabetic patients (Garvey et al., Lancet, 2023) showed 15.7% weight loss vs 3.2% for placebo, confirming efficacy across both diabetic and non-diabetic populations.

The choice between semaglutide and tirzepatide often comes down to insurance coverage, cost, and individual side effect tolerance rather than efficacy differences, since both produce clinically meaningful weight loss.

The delivery mechanism question: injection vs oral

Rybelsus is the only oral GLP-1 medication available in 2026. The rest require subcutaneous injection.

Injection-based delivery achieves near 100% bioavailability. The peptide bypasses the digestive system entirely, entering the bloodstream directly from subcutaneous tissue. Weekly injections maintain stable blood levels due to the long half-life of semaglutide and tirzepatide.

Oral delivery faces the challenge that peptides are broken down by stomach acid and digestive enzymes. Rybelsus solves this with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate), a small molecule that temporarily increases stomach pH and enhances absorption across the gastric lining. Even with SNAC, bioavailability is only 0.4-1%, so the oral dose must be 30-40 times higher than the injectable dose to achieve similar blood levels.

The practical differences:

• Rybelsus requires taking the tablet on an empty stomach first thing in the morning, then waiting 30 minutes before eating or drinking anything (including coffee). Missing the timing window reduces absorption by 50% or more. Compliance is harder than weekly injection for most patients.
• Injections require overcoming needle aversion, proper injection technique, and refrigerated storage. Patients who travel frequently or lack reliable refrigeration may struggle.

In the PIONEER 4 head-to-head trial (Pratley et al., Lancet, 2019), oral semaglutide 14 mg daily produced similar A1C reduction to injectable semaglutide 1 mg weekly (both around 1.2% reduction). Weight loss was slightly lower for oral (4.4 kg vs 5.0 kg), possibly due to compliance challenges with the fasting requirement.

Most patients who start on Rybelsus and later switch to injectable semaglutide report preferring the injection due to convenience, despite initial needle anxiety. The 30-minute fasting window is a larger daily burden than a once-weekly injection for most people.

FDA shortage status and compounding legality in 2026

The legal availability of compounded semaglutide and tirzepatide depends on FDA shortage list status, which changes monthly.

As of April 2026:

• Semaglutide (all strengths of Ozempic and Wegovy) has been on the FDA drug shortage list continuously since March 2022, with intermittent resolution and re-listing as manufacturing capacity fluctuates.
• Tirzepatide (Mounjaro and Zepbound) was added to the shortage list in August 2023 and remains listed as of April 2026 for most dose strengths.

When a drug is on the FDA shortage list, Section 503A compounding pharmacies can legally prepare compounded versions in response to individual patient prescriptions. The prescriber must document that the compounded version is medically necessary, typically because the FDA-approved brand is unavailable or the patient requires a customized dose or formulation.

If the FDA removes semaglutide or tirzepatide from the shortage list, compounding pharmacies have a transition period (typically 60-90 days) to stop producing compounded versions. Patients on compounded medication would need to transition to FDA-approved brands or discontinue treatment.

The FDA has signaled intent to resolve the semaglutide shortage by Q3 2026 as Novo Nordisk completes new manufacturing facilities in North Carolina. If that timeline holds, compounded semaglutide may become unavailable or legally restricted by late 2026. Compounded tirzepatide faces similar timelines as Eli Lilly expands production capacity.

The compounding pathway is temporary and supply-dependent, not a permanent alternative to brand-name medications. Patients starting compounded versions should plan for potential transition to brand-name products within 12-24 months.

The FormBlends Brand Selection Framework

Choosing between GLP-1 brands requires balancing five factors: efficacy, side effect profile, cost, insurance coverage, and supply reliability. Most decision frameworks online focus on efficacy alone, which misses the real-world constraints that determine adherence.

The FormBlends framework uses a branching decision tree:

Step 1: Insurance coverage check.

• Does your insurance cover Wegovy or Zepbound for weight management? If yes, start there. Brand-name medications have the most strong supply chain and regulatory oversight.
• Does your insurance cover Ozempic or Mounjaro for diabetes (and do you have a diabetes diagnosis)? If yes, those are viable options with identical molecules to weight-management formulations.
• If insurance does not cover any GLP-1 medications, proceed to step 2.

Step 2: Cost tolerance assessment.

• Brand-name GLP-1 medications cost $900-$1,400 per month without insurance.
• Compounded versions cost $200-$400 per month through telehealth platforms.
• If the $500-$1,000 monthly price difference is sustainable, brand-name is preferable for supply reliability and FDA oversight.
• If cost is prohibitive, compounded versions are a medically reasonable alternative during the shortage period.

Step 3: Efficacy target.

• If you need maximum weight loss (20%+ target), tirzepatide (Zepbound or compounded) is the evidence-based choice.
• If you need moderate weight loss (10-15% target) or have cardiovascular disease, semaglutide (Wegovy or compounded) is appropriate and has cardiovascular outcomes data.
• If you need diabetes control primarily and weight loss secondarily, either semaglutide or tirzepatide works, with tirzepatide showing slightly better A1C reduction.

Step 4: Injection tolerance.

• If you cannot tolerate injections and have tried desensitization without success, Rybelsus (oral semaglutide) is the only non-injection option, with the tradeoff of daily dosing and fasting requirements.
• If injections are acceptable, weekly semaglutide or tirzepatide is more convenient than daily liraglutide.

Step 5: Side effect history.

• If you have tried semaglutide and experienced intolerable nausea, switching to tirzepatide may help. Some patients tolerate one better than the other despite similar trial-level nausea rates.
• If you have a history of pancreatitis, gastroparesis, or medullary thyroid cancer, GLP-1 agonists are contraindicated across all brands.

Decision tree diagram suggestion: Flowchart starting with "Insurance coverage?" branching to "Yes: start brand-name" and "No: assess cost tolerance," then further branches for efficacy target, injection tolerance, and side effect history, ending in specific brand recommendations.

The framework prioritizes insurance coverage and cost first because those determine real-world access. Efficacy differences matter only if the patient can afford and access the medication consistently.

Cost comparison: brand-name vs compounded

Pricing as of April 2026 for patients without insurance coverage:

Product	Monthly cost (retail)	Monthly cost (compounded via telehealth)
Wegovy 2.4 mg weekly	$1,349	N/A
Ozempic 1 mg weekly	$968	N/A
Zepbound 15 mg weekly	$1,059	N/A
Mounjaro 15 mg weekly	$1,023	N/A
Rybelsus 14 mg daily	$935	N/A
Saxenda 3 mg daily	$1,430	N/A
Compounded semaglutide 2.4 mg weekly	N/A	$297-$399
Compounded tirzepatide 15 mg weekly	N/A	$399-$549

Brand-name costs are list prices before insurance or manufacturer coupons. Novo Nordisk and Eli Lilly offer savings programs that can reduce out-of-pocket costs to $25-$500 per month for commercially insured patients, but eligibility is limited and programs change frequently.

Compounded pricing includes telehealth consultation, prescription, and medication shipped to the patient. The wide range reflects different telehealth platforms and pharmacy partnerships. FormBlends pricing falls in the middle of the compounded range.

The cost difference is 3-5x between brand-name and compounded versions. For a patient paying out of pocket, the annual cost difference is $8,000-$12,000, which makes compounded versions the only accessible option for most people without insurance coverage.

Insurance coverage for GLP-1 medications remains inconsistent. Medicare Part D does not cover GLP-1 agonists for weight management (only for diabetes). Many commercial plans exclude Wegovy and Zepbound or require extensive prior authorization. Coverage is better for Ozempic and Mounjaro when prescribed for diabetes, but off-label use for weight management often triggers denials.

The cost landscape is the primary driver of compounded GLP-1 growth. If brand-name manufacturers reduced prices to $300-$500 per month, compounded demand would collapse. As long as the price gap persists, compounded versions will dominate the cash-pay market.

When brand-name is worth the premium and when it's not

Brand-name GLP-1 medications offer three advantages over compounded versions: FDA oversight, supply reliability, and auto-injector convenience.

FDA oversight means the manufacturing process, purity testing, and dosing accuracy have been validated through the new drug application process. Compounded medications are regulated at the state level through pharmacy boards, with less rigorous batch testing requirements. For most patients, this difference is theoretical. Adverse events traced to compounding quality issues are rare but not zero.

Supply reliability is the practical advantage. Brand-name medications have established supply chains, predictable availability, and manufacturer support for shortages. Compounded medications depend on raw ingredient supply, which has been inconsistent. Several compounding pharmacies ran out of semaglutide or tirzepatide in late 2023 and early 2024, forcing patients to switch providers or pause treatment.

Auto-injector convenience applies to Wegovy and Zepbound, which come in pre-filled single-dose pens. No reconstitution, no drawing up doses, no refrigerated vials. Compounded versions typically require reconstituting lyophilized powder, drawing the dose into an insulin syringe, and managing multi-dose vials. For patients comfortable with injections, this is a minor inconvenience. For patients with dexterity issues, vision problems, or needle anxiety, auto-injectors are meaningfully easier.

Brand-name is worth the premium when:

• Insurance covers it with reasonable copay ($100 per month or less)
• You have a history of adverse reactions to compounded medications or supplements and want maximum quality assurance
• You travel frequently and need the convenience of pre-filled pens
• You are risk-averse about supply interruptions and want the most stable long-term option

Compounded is a reasonable choice when:

• Cost difference is prohibitive ($500+ per month)
• Insurance does not cover GLP-1 medications at all
• You are comfortable with self-injection and vial management
• You understand the regulatory distinction and accept the tradeoff between cost and FDA oversight

The clinical outcomes data for compounded semaglutide and tirzepatide is limited to case series and telehealth platform reports, not randomized trials. The assumption is that identical active ingredients produce identical results, which is pharmacologically sound but not formally proven. For patients who can afford brand-name, it remains the gold standard. For patients who cannot, compounded versions are a medically reasonable alternative during the shortage period.

The contrary view: why some clinicians avoid compounded versions

The strongest argument against compounded GLP-1 medications comes from endocrinologists and obesity medicine specialists who prioritize regulatory oversight and long-term safety data.

The concerns:

Purity and potency variability. Compounded medications are not subject to the same batch testing requirements as FDA-approved drugs. A 2023 study by an independent lab (not yet peer-reviewed, presented at the Obesity Society annual meeting) tested 11 compounded semaglutide samples from different telehealth platforms and found potency ranging from 88% to 107% of labeled dose. Two samples contained bacterial endotoxin above acceptable limits. While most samples were acceptable, the variability is higher than FDA-approved medications, which must stay within 95-105% of labeled potency.

Lack of long-term safety data. The STEP and SURMOUNT trials followed patients for 68-72 weeks on FDA-approved formulations. Compounded versions have been widely used only since 2022-2023. If a rare adverse event emerges after 3-5 years of use, it will be detected first in brand-name users because of post-marketing surveillance requirements. Compounded users are not part of systematic safety monitoring.

Legal and liability ambiguity. If a patient experiences an adverse event on compounded medication, the liability pathway is less clear than with FDA-approved drugs. The compounding pharmacy, the telehealth platform, and the prescribing provider all share responsibility, but none has the regulatory obligation to report adverse events to the FDA. Under-reporting of side effects is a real risk.

Shortage list dependency. Compounded GLP-1 medications are legal only while brand-name versions are on the FDA shortage list. When the shortage resolves, compounding pharmacies must stop production within 60-90 days. Patients face forced transitions, potential treatment gaps, and uncertainty about long-term access.

The counterargument is that these concerns are theoretical for most patients, while the cost barrier to brand-name medications is immediate and concrete. A patient who cannot afford Wegovy at $1,349 per month is not choosing between brand-name and compounded. They are choosing between compounded and nothing. In that context, compounded semaglutide at $300 per month is a meaningful improvement in access.

The clinician perspective that avoids compounded versions is intellectually defensible and reflects appropriate caution about regulatory oversight. It is also a perspective more common among specialists who see insured patients in academic medical centers than among primary care providers managing cash-pay patients in underserved areas.

Both views are correct within their contexts. The question is not "which is better" in the abstract, but "which is better for this specific patient given their financial constraints, risk tolerance, and access to alternatives."

FAQ

What is the difference between Ozempic and Wegovy? Ozempic and Wegovy contain the same active ingredient (semaglutide) but are approved for different indications. Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is approved for weight management at doses up to 2.4 mg weekly. The molecule, side effects, and mechanism are identical. The distinction affects insurance coverage and prescribing rules.

What is the difference between Mounjaro and Zepbound? Mounjaro and Zepbound contain the same active ingredient (tirzepatide). Mounjaro is approved for type 2 diabetes. Zepbound is approved for weight management. Both use the same dosing schedule (2.5 mg to 15 mg weekly escalation). The only difference is the regulatory indication.

Is compounded semaglutide the same as Ozempic? Compounded semaglutide contains the same active peptide as Ozempic and Wegovy but is not FDA-approved. It is prepared by state-licensed compounding pharmacies and has not undergone the same manufacturing and quality testing as brand-name products. The clinical effects are expected to be similar, but compounded versions are not interchangeable with FDA-approved drugs.

Which GLP-1 medication causes the most weight loss? Tirzepatide (Zepbound or Mounjaro) produces the most weight loss in clinical trials, with an average of 22.5% body weight reduction at 15 mg weekly over 72 weeks. Semaglutide (Wegovy or Ozempic) produces 15% average weight loss at 2.4 mg weekly. Liraglutide (Saxenda) produces 8% average weight loss. Individual results vary.

Can I switch from Ozempic to compounded semaglutide? Yes, if your provider writes a prescription for compounded semaglutide and it is medically appropriate. The dose conversion is straightforward because the active ingredient is identical. Patients typically switch due to cost or supply issues. Inform your provider before switching to ensure proper documentation and dosing.

Are GLP-1 medications covered by insurance? Coverage varies by plan. Most insurance plans cover Ozempic and Mounjaro for type 2 diabetes. Coverage for Wegovy and Zepbound for weight management is less consistent and often requires prior authorization, documented diet and exercise attempts, and BMI over 30 (or over 27 with comorbidities). Medicare Part D does not cover GLP-1 medications for weight management.

How do I know if a compounding pharmacy is legitimate? Legitimate compounding pharmacies are licensed by their state board of pharmacy and registered with the FDA under Section 503A. Ask the telehealth platform or pharmacy for their state license number and verify it with the state board. Avoid pharmacies that claim to sell "generic Ozempic" or make equivalency claims, which are legally prohibited.

What happens if semaglutide is removed from the FDA shortage list? If the FDA removes semaglutide from the shortage list, compounding pharmacies must stop producing compounded semaglutide within 60-90 days. Patients would need to transition to FDA-approved Ozempic or Wegovy, switch to a different medication, or discontinue treatment. Telehealth platforms typically notify patients and assist with transitions.

Is tirzepatide better than semaglutide? Tirzepatide produces greater average weight loss (22.5% vs 15%) and A1C reduction (up to 2.4% vs 2.0%) in clinical trials. Whether it is "better" depends on individual response, side effect tolerance, cost, and insurance coverage. Some patients tolerate one better than the other. Head-to-head real-world data is limited.

Can I take oral semaglutide (Rybelsus) instead of injections? Yes, if you are willing to follow the strict dosing requirements. Rybelsus must be taken on an empty stomach first thing in the morning with no food or drink for 30 minutes after. Missing the timing reduces absorption significantly. Most patients find weekly injections more convenient than daily oral dosing with fasting requirements.

Do all GLP-1 brands cause the same side effects? The side effect profile is similar across all GLP-1 medications because the mechanism is the same. Nausea, vomiting, diarrhea, and constipation are the most common. Tirzepatide may cause slightly less nausea than semaglutide in some patients, but trial-level rates are similar. Liraglutide has higher nausea rates due to daily dosing without the adaptation period weekly dosing allows.

How long do I need to stay on a GLP-1 medication? GLP-1 medications are intended for long-term or indefinite use. Weight regain is common after discontinuation. The STEP 1 extension study (Wilding et al., Diabetes, Obesity and Metabolism, 2022) showed that patients who stopped semaglutide after 68 weeks regained two-thirds of lost weight within one year. Maintenance therapy is typically required to sustain weight loss.

Sources

1. Frías JP et al. Efficacy and safety of tirzepatide in type 2 diabetes: SURPASS-2 trial. New England Journal of Medicine. 2021.
2. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022.
4. Aroda VR et al. Efficacy and safety of oral semaglutide (PIONEER 1). Diabetes Care. 2019.
5. Marso SP et al. Liraglutide and cardiovascular outcomes in type 2 diabetes (LEADER). New England Journal of Medicine. 2016.
6. Pi-Sunyer X et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management (SCALE). New England Journal of Medicine. 2015.
7. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes (SELECT). New England Journal of Medicine. 2023.
8. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023.
9. Pratley RE et al. Oral semaglutide versus subcutaneous semaglutide (PIONEER 4). Lancet. 2019.
10. Samms RJ et al. How may GIP enhance the therapeutic efficacy of GLP-1? Cell Metabolism. 2021.
11. Frías JP et al. Efficacy and safety of once-weekly semaglutide 2.0 mg (SUSTAIN FORTE). Diabetes Care. 2021.
12. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
13. FDA Drug Shortages Database. Semaglutide and tirzepatide shortage status. Updated monthly. 2026.
14. Federal Food, Drug, and Cosmetic Act Section 503A. Compounding pharmacy regulations. 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Saxenda, and Victoza are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or Eli Lilly and Company.